Stem Cell Therapy for Diabetes in China: Evidence, Trials & Eligibility
Stem-cell therapy is not a routine established cure for type 1 or type 2 diabetes in China. What does exist is a mix of standard endocrinology, published cell-therapy research, registered clinical trials, and commercial self-pay offers. Those four things should not be treated as the same product.
Short answer: China has produced important diabetes cell-therapy research, including a 2024
first-in-human type 1 diabetes report and an active Phase I islet-cell study. That does not mean a foreign patient
can walk into a clinic and buy the published protocol. Eligibility, study status, hospital acceptance, cell type
and follow-up must be checked case by case.
✓ No cure guarantee
✓ Named hospitals only
✓ Trial status checked when relevant
✓ No obligation to book
Stem-Cell Diabetes Treatment in China: At a Glance
No routine stem-cell cure is established for either type 1 or type 2 diabetes. Standard diabetes care still matters before any experimental pathway.
A 2024 Cell paper reported sustained insulin independence from day 75 in the first treated patient using autologous CiPSC-derived islets.
NCT06731218 is listed as recruiting at Tianjin First Center Hospital for selected adults with type 1 diabetes.
A commercial “stem-cell package” should never be assumed to use the same cells, protocol or eligibility rules as a published study.
Evidence and registry status last checked: September 2026.
What Can “Stem-Cell Treatment” for Diabetes in China Actually Mean?
Before comparing prices or hospitals, identify which pathway you are actually looking at. The same phrase “stem-cell treatment” can describe very different medical and commercial situations.
| Pathway | What it is | What a patient should verify | What it is not |
|---|---|---|---|
| Standard endocrinology | Diagnosis review, insulin/device optimization, type 2 medication strategy, complication assessment. | Hospital, specialist, tests, treatment plan and written quote. | A stem-cell cure. |
| Registered clinical trial | Experimental treatment under a defined protocol with inclusion/exclusion criteria and study oversight. | Registry ID, recruiting status, exact site, eligibility, foreign-patient access and required follow-up. | A guaranteed treatment slot. |
| Published research | A paper describing results in one or more selected patients. | Study population, cell product, protocol, follow-up, adverse events and whether the same programme is currently open. | A product that can automatically be booked. |
| Commercial self-pay package | A marketed treatment offer sold directly or through a facilitator. | Named hospital, cell type, ethics/trial ID if claimed, physician, dosing, inclusions, exclusions, follow-up and total price. | Proof that the offer reproduces a peer-reviewed trial. |
What Does the Evidence Show for Type 1 Diabetes?
Direct answer: The strongest China-specific headline is a first-in-human 2024 report in
Cell. One 25-year-old patient received autologous chemically induced pluripotent stem-cell-derived
islets and achieved sustained insulin independence beginning about 75 days after transplantation. This is an
important proof of concept, but it is not evidence of a routine cure for the general type 1 diabetes population.
Why the result matters
The study showed that patient-derived stem-cell islets could engraft and restore insulin-independent glucose control in the first treated patient at one-year follow-up.
Why the result has limits
It was a one-patient preliminary report. The patient had previously received a liver transplant and was already receiving immunosuppression, so the result does not answer every immune-rejection question for a typical person with type 1 diabetes.
Important: “Insulin independence in one published patient” and “a commercial stem-cell cure available
to any foreign patient” are completely different claims.
Have you been shown a China stem-cell offer for type 1 diabetes?
Send the hospital name, trial ID, brochure or treatment PDF together with your recent diabetes records. We can check what the offer actually represents before you plan travel.
Request a preliminary case review
Tell us the basics of your case. When you submit, WhatsApp will open with the information you entered so you can review it before sending. This is a preliminary routing request, not a diagnosis, treatment acceptance, trial enrollment, visa decision, or medical advice.
What may be useful after first contact
- A recent medical summary or discharge note
- Relevant laboratory results
- Medication/treatment list
- Imaging or specialist reports if relevant
Eligibility and foreign-patient access
There is no universal diabetes-trial or stem-cell eligibility list. Each protocol publishes its own inclusion and exclusion criteria. Recruitment on a registry is not a promise that an international patient can enroll.
| Question | What can be said now | What still needs the site |
|---|---|---|
| Who may be considered | Adults (and, for some pediatric studies only, children) whose diagnosis, C-peptide, hypoglycaemia history and current therapy match a named protocol. Example sourced criteria for RGB-5088 / NCT06731218 include type 1 diabetes, age 18–60, stimulated C-peptide < 0.3 ng/mL, and at least one severe hypoglycaemia in the prior 12 months (public listing; last cross-checked 10 September 2026). | Whether that protocol is still open, whether your labs fit, and whether the site will review overseas files. |
| What may exclude or delay review | Wrong diabetes type for the protocol; untreated proliferative retinopathy; unstable heart or GI disease; active infection or cancer history where the protocol excludes it; inability to attend follow-up. | Site-specific laboratory cut-offs and washout rules. |
| Records usually needed | Diagnosis, year of onset, recent HbA1c, C-peptide and autoantibodies if done, insulin/pump/CGM details, kidney and eye status, medication list, and any prior transplant or immunosuppression. | Certified translations and original imaging if the hospital asks. |
| Can foreigners request prescreening? | Some sites will look at a remote file. That is prescreening, not enrollment. Chinese domestic IND records (for example CTR20244750 for RGB-5088) have also been listed as not yet recruiting even when ClinicalTrials.gov said recruiting — statuses can disagree. | Written confirmation from the study coordinator. |
| Language and remote review | English summaries help. Official screening is usually in Chinese at the hospital. Remote review does not replace on-site consent. | Whether an international-patient office will coordinate. |
| What happens next | File review → site question → hospital reply → only then travel/visa planning. Parkmega does not assign trial slots. | Ethics, insurance, and visit calendar if the site invites you. |
Check whether my case can be reviewed
Sources: ClinicalTrials.gov NCT06731218 public eligibility text; Chinese CTR20244750 status note. Last reviewed 10 September 2026.
Evidence status matrix
Use this table to separate standard care, investigational work, and trial-only routes. Recruitment is not enrollment. A published case is not a product.
| Approach | Status | Evidence type | Typical candidate context | Key uncertainty | Source | Last reviewed |
|---|---|---|---|---|---|---|
| Insulin, metformin, SGLT2, GLP-1 / GIP-GLP-1 | Standard / established | WHO; ADA 2026 | Type 1 insulin; type 2 according to complications | None of these is a stem-cell product | WHO; ADA Standards 2026 | 10 September 2026 |
| Autologous CiPSC islets (Wang et al., Cell 2024; ChiCTR2300072200) | Investigational / trial-only | Peer-reviewed n=1, 1-year follow-up | One published type 1 patient already on immunosuppression after liver transplant | Not a walk-in package; immunosuppression context; more patients not yet published as a product | Cell 187:6152 (2024); ChiCTR2300072200 | 10 September 2026 |
| Zimislecel / VX-880 (NCT04786262) | Investigational (not a China walk-in package) | NEJM 2025 Phase 1/2 interim: 10/12 insulin-independent at day 365 with immunosuppression | Severe hypoglycaemia / unawareness type 1 in that trial | Two deaths in the broader program; immunosuppression risks; not WHO/ADA standard care | NEJM 2025; NCT04786262 | 10 September 2026 |
| UC-MSC type 2 RCT (NCT02302599) | Completed trial (not a current enrollment route) | Phase 2 RCT, n=103, completed | Selected Chinese adults with type 2 in that protocol | Completed; not an advertised “cure rate” | ClinicalTrials.gov NCT02302599 | 10 September 2026 |
| Marketed “stem-cell diabetes packages” | Unverified commercial offer unless a named protocol ID is shown | FDA/FTC warnings on unapproved regenerative ads | Anyone being sold a drip without a registry ID | Price banners are not NMPA-approved replacements for insulin | FDA consumer warnings; FTC regenerative-marketing actions | 10 September 2026 |
See which pathway fits my case
No row is a promise of insulin independence, a trial seat, or a hospital ranking. Last reviewed 10 September 2026.
What Does the Evidence Show for Type 2 Diabetes?
Type 2 diabetes is a different pathway. The most useful China-specific evidence here includes controlled research on mesenchymal stem cells, but trial outcomes should not be converted into a universal “success rate” for commercial packages.
NCT02302599
This randomized placebo-controlled study at Chinese PLA General Hospital evaluated umbilical-cord mesenchymal stem cells in adults with type 2 diabetes. The registered primary endpoint was HbA1c below 7% together with at least a 50% reduction in daily insulin requirement at 48 weeks.
A trial result is not a package success rate
A patient paying for an unrelated commercial infusion cannot assume the same cell source, dose, protocol, selection criteria or outcome as a completed randomized trial.
For type 2 diabetes, the clinically relevant question may be glucose control, weight and metabolic management, remission, complication reduction or trial eligibility — not simply whether a product is labelled “stem cells.”
Diabetes Stem-Cell Clinical Trials in China
Registry status changes. A study being listed online does not automatically mean that a foreign patient can enroll. The hospital or study team must confirm medical eligibility and practical access.
| Study | Diabetes type / approach | China site | Registry status | Foreign-patient access |
|---|---|---|---|---|
| NCT06731218 RGB-5088 Phase I |
Type 1 · islet-cell transplantation | Tianjin First Center Hospital | Recruiting | Not established by the public registry; must be confirmed with the study site. |
| NCT06407297 UCMSC + standard therapy |
Newly diagnosed type 1 · pediatric UCMSC study | Shanghai Changzheng Hospital | Unknown status Last known: recruiting |
Not established by the public registry; re-verification is required before any travel plan. |
| NCT02302599 UC-MSC randomized trial |
Type 2 · umbilical-cord MSC | Chinese PLA General Hospital, Beijing | Completed | Not recruiting; useful as evidence, not as a current treatment route. |
Interested in a specific China diabetes trial?
We can check the current registry record, study site and whether the hospital is willing to consider an overseas case before you book travel.
Which Chinese Hospitals Are Actually Connected to Diabetes Cell-Therapy Research?
A useful hospital name should be connected to a specific department, publication or trial — not just repeated in a medical-tourism list.
Tianjin First Center Hospital
Connected to the 2024 CiPSC-islet publication and the recruiting NCT06731218 Phase I RGB-5088 study.
Shanghai Changzheng Hospital
Sponsor/site of NCT06407297, an allogeneic UCMSC study for newly diagnosed pediatric type 1 diabetes. Public registry status needs re-verification.
Chinese PLA General Hospital
Site and sponsor of the completed NCT02302599 randomized type 2 diabetes UC-MSC study.
Hospital reputation is not the same as access. Before recommending travel, Parkmega checks whether
a relevant department will review the case, whether the programme is currently open and whether overseas patients
can be considered.
How Much Does Stem-Cell Therapy for Diabetes Cost in China?
There is no single official “China diabetes stem-cell price.” Cost depends on whether you are
looking at ordinary hospital care, a registered study or a commercial self-pay package. These must be priced separately.
| Route | What the price usually means | How we treat the number |
|---|---|---|
| Hospital diabetes evaluation | Consultation, labs, imaging or complication work-up as clinically indicated. | Hospital-specific. Request a written estimate for the actual case. |
| Registered clinical trial | The investigational product and protocol-required care may be covered according to the study, while travel, lodging and non-protocol care can still create costs. | Verify directly against the protocol/site before travel. |
| Commercial stem-cell package | Facilitator offers reviewed by Parkmega in 2026 have commonly advertised roughly USD 12,000–25,000. | An advertised market band, not an official hospital tariff and not proof that the package matches a published trial. |
Ask for the cell product, dose, number of administrations, hospital, treating physician, pre-treatment tests, inpatient/outpatient days, follow-up, interpreter, accommodation and refund/cancellation terms in writing.
Who May Be Considered for Experimental Diabetes Cell Therapy?
There is no universal eligibility checklist. Every protocol has its own inclusion and exclusion criteria, but the following information commonly determines whether a study team can even screen a case.
Type 1 diabetes records
- Age and year of diagnosis
- Recent HbA1c and glucose history
- Fasting / stimulated C-peptide when available
- Pancreatic autoantibodies when available
- Severe hypoglycemia and DKA history
- Insulin regimen, CGM and pump data
- Kidney, eye, heart, infection and transplant history
Type 2 diabetes records
- Age, BMI and diabetes duration
- Recent HbA1c
- C-peptide when available
- Daily insulin requirement
- Current GLP-1, SGLT2, metformin and other medication
- Kidney, cardiovascular and eye complications
- Previous metabolic / bariatric treatment if relevant
Parkmega does not decide medical eligibility. The study investigator or treating hospital does. Our role is to organize the records, identify the correct pathway and ask the relevant centre for review.
How Parkmega Checks a Stem-Cell Treatment Claim
Identify the exact hospital
We do not treat “Shanghai” or “Guangzhou” as a medical provider. We need the actual hospital or research centre.
Check the protocol
Cell type, trial or ethics ID, investigator, inclusion criteria, study status and follow-up requirements.
Confirm overseas access
A registry may list a study without saying whether non-Chinese patients can realistically enroll.
Request the treatment route and cost
Travel planning starts only after a named hospital or study team confirms that the case can be reviewed.
What Medical Records Should You Send?
Minimum useful file
- Diagnosis and year diagnosed
- Latest HbA1c
- C-peptide and antibodies if available
- Current insulin / medication list
- Recent kidney and liver function
- Major diabetes complications
If you already found an offer
- Hospital or clinic name
- Doctor / investigator name
- Trial or ethics ID
- Brochure, PDF or screenshot of the offer
- Quoted price and what it includes
- Proposed dates and expected stay in China
Send Your Medical Records Before You Travel to China
We’ll review the diagnosis and documents, identify whether the request belongs to standard treatment, published research, a registered clinical trial or a commercial package, and contact a relevant hospital when there is a realistic route to evaluate.
✓ No obligation to book
✓ Named hospitals only
✓ Trial status checked when relevant
Related Diabetes Guides
Frequently Asked Questions
Short answers to the questions international patients most often ask before contacting a hospital.
Can stem cells cure type 1 diabetes in China?
No routine stem-cell cure is established for type 1 diabetes. A 2024 first-in-human Chinese study reported sustained insulin independence in one patient after autologous CiPSC-derived islet transplantation, and follow-up research is continuing. That is proof of concept, not a treatment available to every patient.
What is the success rate of stem-cell therapy for type 2 diabetes in China?
There is no reliable universal success rate for commercial self-pay stem-cell packages. A completed Chinese randomized UC-MSC study in type 2 diabetes used a defined primary endpoint and narrow eligibility criteria, but those trial results should not be applied to unrelated commercial offers.
Which China stem-cell diabetes trial is currently recruiting?
As checked in September 2026, ClinicalTrials.gov lists NCT06731218 as recruiting at Tianjin First Center Hospital. It is a Phase I study of RGB-5088 islet-cell transplantation for selected adults with type 1 diabetes. Foreign-patient acceptance is not established by the public registry and must be confirmed with the study site.
How much does stem-cell therapy for diabetes cost in China?
There is no single official national price. Commercial facilitator offers reviewed by Parkmega in 2026 have commonly advertised roughly USD 12,000–25,000, but that is an advertised market range, not a hospital-wide tariff and not proof that the package matches a registered trial. Trial-related and standard hospital costs must be verified separately.
Can foreign patients join a diabetes clinical trial in China?
Sometimes, but it cannot be assumed from a registry listing alone. The study team must confirm medical eligibility, nationality or residency restrictions, language requirements, follow-up schedule and whether the site is willing to enroll an overseas patient.
What records should I send for a China diabetes case review?
Send the diabetes type and year of diagnosis, recent HbA1c, C-peptide and pancreatic autoantibodies when available, current insulin or medication list, relevant kidney/eye/heart/infection history, and any hospital name, trial ID, brochure or treatment PDF you have already received.
Evidence and Primary Sources
- World Health Organization — Diabetes fact sheet. Type 1 diabetes is characterized by deficient insulin production and requires daily insulin administration.
- American Diabetes Association, Standards of Care in Diabetes—2026, Section 9. Current pharmacologic treatment recommendations for type 1 and type 2 diabetes, including insulin-based therapy and beta-cell replacement context.
- Wang S. et al., Cell (2024), PMID 39326417, DOI 10.1016/j.cell.2024.09.004. First-in-human preliminary report of autologous CiPSC-derived islet transplantation in one type 1 diabetes patient.
- ClinicalTrials.gov NCT06731218. Phase I RGB-5088 islet-cell study at Tianjin First Center Hospital; listed as recruiting when checked in September 2026.
- ClinicalTrials.gov NCT06407297. UCMSC study for newly diagnosed pediatric type 1 diabetes at Shanghai Changzheng Hospital; public registry record requires status re-verification.
- ClinicalTrials.gov NCT02302599. Completed randomized placebo-controlled UC-MSC study in Chinese adults with type 2 diabetes at Chinese PLA General Hospital.
- Zang L. et al., Stem Cell Research & Therapy (2022), PMID 35505375. Published results from the type 2 diabetes UC-MSC randomized trial.
Medical note: Experimental cell-therapy evidence changes quickly. A patient’s own endocrinologist should review any proposed protocol. This page is for medical-travel research and hospital matching; it is not medical advice, a treatment recommendation or a guarantee of trial enrollment.
Want Us to Check a Specific China Treatment or Trial?
Send your records plus the hospital name, study ID, brochure or quote you already have. We’ll separate published evidence from marketing and ask a relevant centre whether your case can be reviewed.